Register for our free email digests:
Dean Rudge
Senior Reporter
Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries in his five years with Generics bulletin. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent-infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.
Writes for:
Latest From Dean Rudge
H2 Pharma Offloads Minority Interest To Private Equity
H2 Pharma, which specializes in both generic and OTC liquid formulations, is looking to climb to the next level after receiving an equity investment from Ardian.
Hikma Eyes Another Hybrid Injectable With Arecor
London-listed Hikma has signed a second partnership agreement with Arecor, proposing to co-develop a 505(b)(2) hybrid injectable product for the US market.
Zentiva Continues European Endeavors With Greek Partnership
Zentiva has struck a new partnership to expand its already significant operations in Europe, this time in Greece with local firm Lavipharm.
Mylan Obtains CHMP Backing For Revlimid Generic In Two Indications
Mylan is taking aim at a lucrative oral solid formulation in Europe, with the European Medicines Agency’s Committee for Medicinal Products for Human Use recommending approval for the company’s generic version of Revlimid (lenalidomide) capsules.
Roche’s Biosimilar Losses Could Be Closer To CHF5bn
Roche entered the year with a projected hit to revenues from multi-source biosimilar competition to its three leading biologics. However, the number was increased at the half-year mark and could be set to ratchet up further, according to management.
Ultomiris FDA Approval Gives Soliris Biosimilars Bigger Hurdle
Alexion Pharmaceuticals’ Soliris (eculizumab) blockbuster represents a significant opportunity for biosimilar sponsors around the globe. Ahead of anticipated US competition in 2025, the originator has added a new formulation for next-generation product Ultomiris (ravulizumab-cwvz).